Concepedia

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

Zhihuang Hu, Ying Cheng, Hongyu Zhang, Caicun Zhou, Baohui Han, Yiping Zhang, Cheng Huang, Jianhua Chang, Xiangqun Song, Jun Liang,

Supportive Care in Cancer · 2013 · 44 citations · 20 references

DOI

Concepts

References

20

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 776 citations

, , +17

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

S. Poli-Bigelli, José Rodrigues-Pereira, Alexandra D. Carides et al. · Cancer · 2003 · 566 citations

, , +17

Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

Steven M. Grunberg, Robert Deuson, Panagiotis Mavros et al. · Cancer · 2004 · 470 citations · Full text

, , +15

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla et al. · New England Journal of Medicine · 1999 · 371 citations · Full text

, , +16

Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings

Lorenzo Cohen, Carl A. de Moor, Peter D. Eisenberg et al. · Supportive Care in Cancer · 2006 · 328 citations

, , +17